

This document is the Accepted Manuscript version of a Published Work that appeared in final form in Organometallics copyright © American Chemical Society, after peer review and technical editing by the publisher. To access the final edited and published work see <https://doi.org/10.1021/om070127y>

ortho-Palladation and Functionalization of L- Phenylalanine Methyl Ester

José Vicente,[†] Isabel Saura-Llamas,^{‡,} José-Antonio García-López, and Beatrice Calmuschi-
Cula*

Grupo de Química Organometálica, Departamento de Química Inorgánica, Facultad de
Química, Universidad de Murcia, Apartado 4021, E-30071 Murcia, Spain

Delia Bautista

SAI, Universidad de Murcia, Apartado 4021, E-30071 Murcia, Spain

[†] E-mail: jvs1@um.es. WWW: <http://www.um.es/gqo/>

[‡] E-mail: ims@um.es

The *ortho*-metalated complex (S,S) -[Pd₂{κ²-C,N-C₆H₄CH(CO₂Me)NH₂-2}₂(μ-Br)₂] (**1b**) can be prepared by refluxing in acetonitrile equimolecular amounts of Pd(OAc)₂ and L-phenylalanine methyl ester hydrochloride, followed by addition of excess of NaBr. Complex **1b** reacts with 4-picoline to give the mononuclear derivative (S) -[Pd{κ²-C,N-C₆H₄CH₂CH(CO₂Me)NH₂-2}₂Br(NC₅H₄Me-4)] (**2**), which crystal structure has been determined by X-ray diffraction. The precursor of **1b**, (S,S) -[Pd₂{κ²-C,N-C₆H₄CH(CO₂Me)NH₂-2}₂(μ-Cl)₂] (**1a**) could not be isolated in a pure form, but it can be used as starting material for the synthesis of functionalized derivatives of the phenylalanine methyl ester. Thus, CO and RNC (R = Xy, ^tBu) insert into the Pd–C bond of **1a**, to afford, after depalladation, (S) -methyl 1-oxo-1,2,3,4-tetrahydroisoquinoline-3-carboxylate (**3**) and (S) -methyl 1-R-iminium-1,2,3,4-tetrahydroisoquinoline-3-carboxylate triflate (R = ^tBu (**4**), Xy (**5**)), respectively. Reaction of complex **1b** with bromine or iodine affords *trans*- (S,S) -[PdBr₂{NH₂CH(CO₂Me)CH₂C₆H₄-X-2}₂] (X = Br (**6**), I (**7**)), which further reacts with 1,10-phenanthroline (phen) to give [PdBr₂(phen)] and (S) -2-X-phenylalanine methyl ester (X = Br (**8**), I (**9**)).

Introduction

ortho-Palladation of (*S*)-phenylalanine (L-phenylalanine) raises an interesting problem. If the free amino acid is used, N,O-chelates involving the deprotonated carboxyl group may be formed,¹ as it has been described for other amino acids.² For instance, 4-iodo-L-phenylalanine reacts with $[\text{PdCl}_2(\text{PEt}_3)]_2$ to give the N,O-chelate complex (*S*)- $[\text{Pd}\{\kappa^2\text{-N,O-NH}_2\text{CH}(\text{CH}_2\text{C}_6\text{H}_4\text{I-4})\text{CO}_2\}\text{Cl}(\text{PEt}_3)]$.³ The carboxylate groups of amino acids can be prevented from coordinating to the metal by using ester derivatives.^{4,5} Even though, a second problem remains: *ortho*-metalation of primary amines has been reported to be difficult, especially if the metallacycle to be formed is a six-membered ring.⁶ This second issue has been avoided by using functionalized⁷ or N-substituted^{4,8} amino groups. However, *ortho*-metalation of primary amines is difficult, but it can be carried out if appropriate experimental conditions are used.⁹⁻¹⁴

ortho-Palladated (*S*)-phenylalanine complexes are interesting for at least three reasons. First of all, palladium complexes containing amino acids as ligands¹⁵⁻¹⁷ as well as cyclopalladated complexes^{17,18} have attracted great interest because their potential cytotoxic activity. Secondly, they can be useful precursors to prepare functionalized derivatives of L-phenylalanine, since complexes containing cyclopalladated amines have found widespread application in organic synthesis.¹⁹⁻²¹ Among the possible derivatives, the *ortho*-halogenated amino acids are particularly interesting, as they are not easily prepared by other methods, such as direct electrophilic substitution, and, in addition, they can be used for preparing other amino acids through palladium-catalyzed reactions. Barluenga et al. have recently reported a regioselective method to prepare *ortho*-iodinated phenylalanine-containing peptide sequences,²² but the method cannot be applied to the methyl ester of the amino acid.²³ Finally, optically active palladacycles are suitable auxiliary reagents for the resolution of racemic

mixtures and determination of enantiomeric purity and absolute configuration of chiral phosphines,^{12,24} amino acids,²⁵ and other ligands.²⁶

Fuchita et al. reported the cyclopalladation of (*R*)-2-phenylglycine methyl ester, an amino acid derivative with an unprotected amino group which gives a five-membered palladacycle, by reacting palladium acetate with the hydrochloride salt of the amino acid ester in acetone.²⁷ Nevertheless, the same reaction conditions were reported to fail when trying to prepare the analogous compound containing (*S*)-phenylalanine methyl ester, our target complex in this article.

Insertion of CO into the Pd–C bond of *ortho*-palladated tertiary amines has been widely investigated,^{8,19,28-30} whereas the same reaction with primary benzylamines has been only superficially examined. Thus, a preliminary communication by Parkins et al. in 1984 described the reaction of $[\text{Pd}(\kappa^2\text{-C,N-C}_6\text{H}_4\text{CH}_2\text{NH}_2\text{-2})\text{I}]_2$ with CO in methanol at room temperature to give phthalimidine and palladium metal, although experimental procedures and the yield were not stated.³¹ Dyke et al. in 1986 observed a similar reaction using chloroform or benzene as solvent, although the expected phthalimidine was not obtained pure.³² We report here that (*S*)-1-oxo-3-methoxycarbonyl-1,2,3,4-tetrahydroisoquinoline can be obtained by carbonylation of *ortho*-palladated (*S*)-phenylalanine methyl ester. This is a particularly interesting compound³³ as it has been extensively used to study the steric course and stereospecificity of α -chymotrypsin-catalyzed reactions.^{34,35} It has also been used as antiallergic agent, to prevent the physical manifestation of atopic allergic reactions.³⁶ Recently, a convenient large-scale synthesis of the *R* enantiomer has been reported, using the amino acid methyl ester and triphosgene as starting materials.³⁷

The reaction of five-membered cyclopalladated benzylamines and isocyanides allows the isolation of the corresponding isoindolinium salts.^{31,38} Here we report that the six-


membered cyclopalladated (*S*)-phenylalanine methyl ester allows the synthesis of tetrahydro isoquinolines.

Results and Discussion

Synthesis and Structure of *ortho*-Metalated Complexes. When (*S*)-PhCH₂CH(CO₂Me)NH₂·HCl (L-phenylalanine hydrochloride) is reacted with Pd(OAc)₂ in 1:1 molar ratio in acetonitrile for 6 days, an orange solid **A** is isolated, which ¹H NMR shows very broad signals that cannot be easily assigned. Nevertheless, in the aromatic region of the spectrum, there are signals corresponding to the *ortho*-metalated and the non-*ortho*-metalated aryl ring of the starting amino acid derivative. There are also two signals in the region corresponding to the OMe groups, which relative integrals indicate an average molar ratio 1:0.3. On the other hand, no acetate signals are present. The components of the mixture cannot be separated by fractional crystallization or by chromatography, although its reactivity shows that the *ortho*-metalated complex (*S,S*)-[Pd₂{κ²-*C,N*-C₆H₄CH₂CH(CO₂Me)NH₂-2}₂(μ-Cl)₂] (**1a**) is the main component (Scheme 1). Thus, this mixture **A** can be used as starting material to synthesize in good yields some derivatives of **1a**.

Other reaction conditions (solvent, temperature, time) were tested to prepare **1a**: i) acetonitrile at 80 °C for 4-8 h; ii) toluene at 60 or 75 °C for 12 h; iii) acetic acid at 60 °C for 24 h. In all cases, decomposition to Pd(0) took place and the mixture obtained was not as rich in **1a** (tested by ¹H-NMR) as in **A**. However, we succeeded in isolating the pure bromo-bridged dinuclear *ortho*-metalated complex (*S,S*)-[Pd₂{κ²-*C,N*-C₆H₄CH₂CH(CO₂Me)NH₂-2}₂(μ-Br)₂] (**1b**), by reacting the mixture **A** with NaBr and recrystallizing the crude product. 4-Picoline (pic) splits the bromide bridges in complex **1b** to give the mononuclear complex (*S*)-[Pd{κ²-*C,N*-C₆H₄CH₂CH(CO₂Me)NH₂-2}Br(pic)] (**2**). Of the two possible isomers for

complex **2**, only the one with the two nitrogen atoms in mutually *trans* position is obtained, as proved by ^1H , ^{13}C NMR and X-ray diffraction studies. This is the normal behavior for benzylamine palladacycles,^{21,39} although a notable exception has recently been reported.⁴⁰



Scheme 1

The ^1H and ^{13}C NMR spectra of complexes **1b** and **2** are in agreement with the proposed structures. The ^1H NMR spectrum of complex **1b** shows a set of three different signals, corresponding to the four remaining protons in the *ortho*-metalated ring: H3 (see numbering scheme in experimental section) appears as a doublet at 7.38 ppm, H5 as a triplet at 6.88 ppm, and H4 and H6 as a multiplet between 6.76–6.91 ppm. A similar pattern is observed in the ^1H NMR spectrum of the mononuclear complex **2** although, in this case, H3 is significantly shifted to lower frequencies ($\Delta\delta = -0.92$ ppm) due to the anisotropic shielding from the picoline ring.⁴¹ In the ^{13}C NMR spectra of complexes **1b** and **2**, the resonances due to the carbon atoms bonded to Pd (140.8 ppm, **1b**; 147.4 ppm, **2**) are deshielded with respect to that of the corresponding free ligand (129.3 ppm in DMSO-d^6), as observed in other cyclopalladated complexes.^{13,14,42}

The crystal structure of complex **2** (Figure 1) shows the palladium atom in a distorted square-planar environment (mean deviation of the plane 0.09 Å) with a dihedral angle of 8.3°

between the N(1)–Pd(1)–C(1) and N(2)–Pd(1)–Br(1) planes. The chelated amino acid ligand forms a six-membered metalacycle with a boat conformation. These features are similar to those of analogous complexes containing other phenethylamine derivatives.^{11,13} The nitrogen atom of the amine and the nitrogen atom of 4-picoline are mutually *trans* and the pyridine ring is rotated 65.3° with respect to the phenyl ring to avoid steric hindrance.




Figure 1. Thermal ellipsoid plot (50% probability) of **2** along with the labeling scheme. Selected bond lengths (Å) and angles (°): Pd(1)–Br(1) 2.5458(6), Pd(1)–N(1) 2.066(4), Pd(1)–C(1) 1.999(5), Pd(1)–N(2) 2.054(4), Br(1)–Pd(1)–N(1) 85.39(12), N(1)–Pd(1)–C(1) 92.19(18), C(1)–Pd(1)–N(2) 90.22(17), N(2)–Pd(1)–Br(1) 92.81(11).

Each molecule of complex **2** is connected to other four molecules through hydrogen bonds, giving a tridimensional network. Along the *b* axis, two adjacent molecules (A and C; Figure 2) are associated through a double interaction between the bromine atom of one molecule (C) and one hydrogen of the methyl group of the other (A) (Br1C··H10A–C10A) and one hydrogen of the amino group of the later molecule (A) and the oxygen atom of the carbonyl group of the former (A) (N1C–H01C··O2A). Besides, the same bromine atom is

associated with two aromatic picoline hydrogens, belonging each of them to other two different molecules (Figure 3).




Figure 2. View of the hydrogen bond interactions along the *b* axis in complex 2. Only Pd and atoms involved in the H bonding are labeled. Details (including symmetry operators) are given in the Supporting Information.





Figure 3. View of the hydrogen bond interaction between aromatic hydrogen and bromine atoms in complex 2. Only Pd and atoms involved in the H bonding are labeled. Details (including symmetry operators) are given in the Supporting Information.

Reaction with Carbon Monoxide. Synthesis of (*S*)-1-oxo-3-methoxycarbonyl-1,2,3,4-tetrahydroisoquinoline (3). As stated in the Introduction, two previous works described the reaction of $[\text{Pd}(\kappa^2\text{-C,N-C}_6\text{H}_4\text{CH}_2\text{NH}_2\text{-2})\text{I}]_2$ with CO to give phthalimidine and palladium metal, although the experimental procedures and the yield were not stated in the first one³¹ and the phthalimidine was not obtained pure in the other.³² The reaction of the mixture **A** with CO in CHCl_3 at room temperature have allowed us to prepare (*S*)-1-oxo-3-methoxycarbonyl-1,2,3,4-tetrahydroisoquinoline (**3**) (Scheme 2). The good isolated yield (64% from phenylalanine methyl ester hydrochloride) proves that **A** is mainly the *ortho*-metalated complex **1a**.


The reaction conditions used to prepared the tetrahydroisoquinoline derivative **3** are milder than those used in analogous reactions to prepare 2-methyl-phthalimidine from *ortho*-palladated N,N-dimethylbenzylamine (xylene, 100 °C and 1 atm of CO-pressure²⁸ or CH_2Cl_2 , room temperature and 2 atm of CO-pressure²⁹) but similar to those used to prepare 2-methyl-3-carboxymethyl-phthalimidine from *ortho*-palladated N,N-dimethylphenylglycine,⁸ although in the later, a nitrogen atmosphere was used. As mentioned in the Introduction, **3** has been used to study the steric course and stereospecificity of α -chymotrypsin-catalyzed reactions,^{34,35} and as antiallergic agent, to prevent the physical manifestation of atopic allergic reactions.³⁶ Compound **3** has been synthesized mostly by cyclation of N-acyl β -arylethylamines, through procedures that involve some drastic reaction conditions or moisture sensitive catalysts.^{34,43} Recently, a convenient large-scale synthesis of the *R* enantiomer has been reported, using the amino acid methyl ester and triphosgene as starting materials.³⁷



Scheme 2. Synthesis of (*S*)-1-oxo-3-methoxycarbonyl-1,2,3,4-tetrahydroisoquinoline (**3**).


Orito et al. have reported a Pd(II)-catalyzed carbonylation of *N*-alkyl-*o*-arylalkylamines to afford five or six-membered benzolactams.⁴⁴ In these conditions, carbonylation of primary amines does not produce benzolactams but ureas. The key step in these reactions seems to be the metalation of the amine. This result is not surprising since *ortho*-metalation of primary amines does not occur in the used reaction conditions when an excess of amine is present.⁴⁵ Our method, although not catalytic, allows the synthesis of a benzolactam from a primary amine and CO.

Reactions with Isocyanides. Synthesis and Structure of [(*S*)-methyl 1-*R*-iminium-1,2,3,4-tetrahydroisoquinoline-3-carboxylate] triflate [R = ^tBu (4**), 2,6-Me₂C₆H₃ (**5**)].** It has been reported that reaction of cyclopalladated benzylamines and isocyanides in refluxing toluene allows the isolation of the corresponding isoindolinium salts.^{31,38} The present availability of cyclopalladated phenethyl amines prompted us to extend this work to the synthesis of six-membered *N*-heterocycles. Thus, the mixture **A** was treated with isocyanide (RNC, R = ^tBu, Xy) and thallium(I) triflate (1:2:2). After removing TlCl, the resulting solution was refluxed in toluene for 7 hours, upon which time formation of Pd(0) was observed. From the mother liquors, the tetrahydro isoquinoline derivatives **4** and **5** could be isolated (Scheme 3).



Scheme 3

According to previous studies,^{8,38,46} it is reasonable to assume that the first step in the formation of the tetrahydro isoquinoline derivative is the coordination of the isocyanide to the *ortho*-metalated fragment to give the adduct **B**, followed by insertion into the Pd–C bond to give an iminoacyl complex **C**. There are some examples of such dimeric bridging iminoacyl palladium complexes.^{29,47} The instability of this triflate derivative and the strain of the seven-membered ring can explain its decomposition and the formation of palladium(0) and the salt **4** or **5**.



Scheme 4. Proposed reaction pathway for the synthesis of **4** and **5**.

These reactions can be performed without thallium triflate, but yields are lower. Besides, a mixture of the chloride salts and the free bases are obtained (tested by ^1H NMR).

Recently, Saluste et al. have reported the palladium catalyzed synthesis of cyclic amidines, starting from 2-bromobenzylamine or 2-bromophenethylamine, $^t\text{BuNC}$ and CsCO_3 .⁴⁸ Nevertheless, it is necessary to point out the restricted availability of 2-halobenzylamines and the limitations of the process, that seems to give only good yields for *tert*-alkylisonitriles.

The ^1H and ^{13}C NMR spectra of compounds **4** and **5** are in agreement with the proposed structures. Additionally, the crystal structure of both compounds have been determined by X-ray diffraction. The similar N–C bond distances in the groups N(2)–C(9)–N(1) [N(2)–C(9) 1.3215(18), C(9)–N(1) 1.3248(18) Å] (**4**) and N(1)–C(17)–N(2) [N(1)–C(17) 1.318(3), C(17)–N(2) 1.312(3) Å] (**5**) and the significantly longer distances of N(1) and N(2) with their other neighbors [N(2)–C(10) 1.4990(17), N(1)–C(8), 1.4625(16) Å (**4**); N(1)–C(1) 1.443(3), N(2)–C(18), 1.457(3) Å (**5**)] suggest that a delocalization of electron density occurs between the atoms N(2), C(9) and N(1) in **4**, and N(1), C(17) and N(2) in **5**. Additionally, the angles C(9)–N(2)–C(10) [129.35(12)°] in **4** and C(17)–N(1)–C(1) [124.45(19)°] in **5** are far away from the sp^3 hybridization for N(2) and N(1), respectively, if a lone pair were assumed on these atoms. The atoms C(8), N(1), C(9), C(2), N(2) and C(10) in **4** and C(18), N(2), C(17), C(11), N(1) and C(1) in **5** are coplanar (mean deviation from the plane 0.0459 and 0.0417 Å, respectively).

In both compounds, the cationic units are connected to the triflate groups through hydrogen bonds (nine interactions with three different triflates for compound **4**, and six interactions with three different triflates for compound **5**). In the cation of compound **5**, there is also a hydrogen bond between the oxygen atom of the C=O group and one aromatic

hydrogen of the phenyl ring (O1A \cdots H15D–C15D). This interaction leads to zig-zag chains along the *b* axis (see Figure 6).




Figure 4. Thermal ellipsoid plot (50% probability) of the cation of **4** along with the labeling scheme. Selected bond lengths (Å) and angles (°): N(2)–C(10) 1.4990(17), N(2)–C(9) 1.3215(18), N(1)–C(9) 1.3248(18), N(1)–C(8) 1.4625(16), C(2)–C(9) 1.4809(18), C(9)–N(2)–C(10) 129.35(12), C(9)–N(1)–C(8) 122.87(12), N(1)–C(9)–N(2) 121.78(13), N(1)–C(9)–C(2) 118.46(12), N(2)–C(9)–C(2) 119.75(12).




Figure 5. Thermal ellipsoid plot (50% probability) of the cation of **5** along with the labeling scheme. Selected bond lengths (Å) and angles (°): N(1)–C(1) 1.443(3), N(1)–C(17) 1.318(3), N(2)–C(17) 1.312(3), N(2)–C(18) 1.457(3), C(17)–C(18) 1.479(3), C(1)–N(1)–C(17) 124.45(19), C(17)–N(2)–C(18) 122.54(19), N(2)–C(17)–N(1) 120.8(2), N(2)–C(17)–C(11) 119.22(19), N(1)–C(17)–C(11) 120.00(19).





Figure 3. View of the hydrogen bond interaction between aromatic hydrogen and oxygen atoms of C=O group in compound **5**. Only atoms involved in the H bonding are labeled. Details (including symmetry operators) are given in the Supporting Information.

Synthesis and Structure of 2-Halo Derivatives. Stoichiometric aromatic halogenation of tertiary amines through cyclopalladated complexes is a known process.^{19,49,50} However, the extension to the corresponding primary amines has only very recently reported by us.¹⁴ The reaction of complex **1b** with Br₂ or I₂, in CH₂Cl₂ at room temperature, afforded *trans*-[PdBr₂{NH₂CH(CO₂Me)Me₂CH₂C₆H₄X-2}₂] (X = Br, **6**; I, **7**) in good yields (Scheme 3). We have proposed that the initial step of the reaction is the oxidative addition of iodine or bromine to give a Pd(IV) complex (see **D** in Scheme 4).¹⁴ This complex would then undergo a reductive elimination, to give **E**, followed by a symmetrization process, leading to **6** or **7** and PdX₂. A Pd(II) complex similar to the proposed intermediate **E** has been reported by Espinet et al.⁵⁰ Pure palladium bromide or palladium iodide was quantitatively isolated from the reaction mixture by filtration, as a dark brown solid. It is interesting to note that, when I₂ is used as oxidative agent, only PdI₂ and the dibromo complex **7** are formed. These solids were then reacted with PPh₃ (1:2) to give [PdBr₂(PPh₃)₂] or [PdI₂(PPh₃)₂], which were characterized by ³¹P NMR.



Scheme 4. Proposed reaction pathway for the synthesis of 2-halo derivatives of phenylalanine methyl ester **8** and **9**.

(*S*)-2-Bromo-phenylalanine methyl ester (**8**) and (*S*)-2-iodo-phenylalanine methyl ester (**9**) were conveniently prepared by reacting the corresponding precursor (**6** or **7**) with 1,10-phenanthroline (phen). The iodo derivatives **7** and **8** decompose slowly at room temperature. The by-product in these reactions, $[\text{PdBr}_2(\text{phen})]$, precipitates from the reaction mixtures and can be easily separated from the final amines by filtration (Scheme 4). Curiously, an analogous complex, $[\text{PdCl}_2(\text{phen})]$, has been reacted with various aminoacids in the presence of a base to prepare palladium(II) N,O-chelated amino acidato complexes with cytotoxic activity.¹⁶

Substitution of the Pd atom by bromine or iodine was confirmed by ^{13}C NMR spectroscopy. The resonance due to the aromatic carbon atom bonded to Br or I ($\delta = 124.7$, **8**; 100.8 , **9**) is shifted to lower frequency with respect to the corresponding signals in the cyclometalated complex **1b** ($\delta = 140.8$) and in the free ligand ($\delta = 129.3$, DMSO- d_6). This is

a well-known effect.⁵¹ In addition, the ¹H NMR spectra of the 2-halo amino acid methyl esters **8** and **9** showed the signals corresponding to the NH₂ groups shifted to lower frequency with respect to those of **6** and **7**, as expected upon palladium de-coordination.

Conclusions

Using the appropriate experimental conditions, L-phenylalanine methyl ester can be *ortho*-metalated. The crystal structure of the mononuclear complex containing 4-picoline has been determined by X-ray diffraction. The cyclopalladated compound is an excellent starting material to prepare, in a stereospecific form, functionalized derivatives of this amino acid, as tetrahydro isoquinolines and 2-halo phenylalanine methyl esters.

Experimental Section

General procedures. Infrared spectra were recorded on a Perkin Elmer 16F-PC-FT spectrometer. C, H and N analyses and melting point determinations were carried out as described elsewhere.⁹ Unless otherwise stated, NMR spectra were recorded in CDCl₃ with Bruker Avance 300 or 400 spectrometers. Chemical shifts are referenced to TMS (¹H and ¹³C{¹H}) or H₃PO₄ (³¹P{¹H}). Signals in the ¹H and ¹³C NMR spectra of all complexes were assigned with the help of HSQC and HMBC techniques. FAB MS measurements were carried out from liquid samples using 3-nitrobenzyl alcohol as a matrix in a VG Autospec E apparatus. Chromatographic separations were carried out by TLC on silica gel 60 ACC (70-230 mesh). Reactions were carried out at room temperature without special precautions against moisture. L-Phenylalanine methyl ester hydrochloride, 4-methylpyridine (4-picoline), 2,6-dimethylphenyl isocyanide (xylyl isocyanide), *tert*-butyl isocyanide, PPh₃ (Fluka), 1,10-

phenanthroline monohydrate, (Merck) and palladium acetate (Johnson Matthey) were used as received. TlOTf (TlSO₃CF₃) was prepared by reaction of Tl₂CO₃ and HSO₃CF₃ (1:2) in water and recrystallized from acetone/Et₂O.

Caution! Special precautions should be taken in handling thallium(I) compounds because of their toxicity.

Synthesis of (S,S)-[Pd₂{κ²-C,N-C₆H₄CH₂CH(CO₂Me)NH₂-2}₂(μ-Br)₂] (1b). L-phenylalanine methyl ester hydrochloride (1.00 g, 4.64 mmol) was added to a solution of Pd(OAc)₂ (1.04 g, 4.64 mmol) in acetonitrile (60 mL), and the resulting solution was stirred at room temperature for 6 days. A small amount of metallic palladium was formed. The mixture was filtered through a plug of MgSO₄, the filtrate was concentrated to dryness, the residue dissolved in CH₂Cl₂ (5 mL) and Et₂O (30 mL) was added to precipitate an orange solid which was filtered, washed with Et₂O (2 x 2 mL) and air-dried (1.26 g). ¹H NMR of this solid in CDCl₃ shows very broad peaks, difficult to assign, but the analysis of the aromatic region indicates a mixture 1:0.35 of the *ortho*-metalated complex [Pd₂{κ²-C,N-C₆H₄CH₂CH(CO₂Me)NH₂-2}₂(μ-Cl)₂] and other non-*ortho*-metalated species such as [Pd₂(μ-Cl)Cl{NH₂CH(CO₂Me)CH₂Ph}₂] or [Pd₂Cl₂{NH₂CH(CO₂Me)CH₂Ph}₂]. This mixture **A** could not be separated neither by fractional crystallization nor by chromatography. To a solution of mixture **A** (950 mg) in acetone (50 mL), NaBr (1.5 g, 19.4 mmol) was added. The reaction mixture was stirred for 12 h and acetone was evaporated. The residue was taken in CH₂Cl₂ (30 mL), the suspension filtered through a plug of MgSO₄, the filtrate was concentrated to dryness, and Et₂O (30 mL) was added. The orange solid obtained was filtered, washed with Et₂O (2 x 2 mL) and air-dried to afford crude complex **1b**. Yield: 631 mg, 0.866 mmol, 49%. An analytically pure sample of complex **1b** was obtained by recrystallization of CH₂Cl₂/Et₂O. Mp: 147 °C dec. Anal. Calcd for C₂₀H₂₄Br₂N₂O₄Pd₂ (729.03): C, 32.95; H,

3.32; N, 3.84. Found: C, 33.49; H, 3.54; N, 4.15. IR (cm⁻¹): $\nu(\text{NH}) = 3280, 3234$; $\nu(\text{CO}) = 1732$. ¹H NMR (300 MHz): δ 3.31 (dd, 1 H, CH₂, ²J_{HH} = 13.6, ³J_{HH} = 3.7 Hz), 3.51 (s, 3 H, OMe), 3.82 (br d, 1 H, CH₂), 4.23 (br s, 2 H, NH₂), 4.30 (br s, 1 H, CH), 6.76–6.82 (m, 2 H, H4 and H6, C₆H₄), 6.88 (t, 1 H, H5, C₆H₄, ³J_{HH} = 7.2 Hz), 7.38 (d, 1 H, H3, C₆H₄, ³J_{HH} = 7.5). ¹³C{¹H} NMR (75.45 MHz): δ 45.5 (s, CH₂), 49.8 (s, CH), 52.8 (s, OMe), 124.7 (s, CH, C5, C₆H₄), 125.3 (s, CH, C4, C₆H₄), 127.5 (s, CH, C6, C₆H₄), 134.4 (s, C, C1, C₆H₄), 136.9 (s, CH, C3, C₆H₄), 140.8 (s, C, C2, C₆H₄), 172.3 (s, CO).

The mixture **A** was used as starting material for the synthesis of compounds **3**, **4** and **5**. Crude complex **1b** was used as starting material for the synthesis of complexes **2**, **6** and **7**.




Chart 1. Numbering scheme for complex **1b** and tetrahydro isoquinoline derivatives.

Synthesis of (S)-[Pd{ κ^2 -C,N-C₆H₄CH₂CH(CO₂Me)NH₂-2}₂Br(NC₅H₄Me-4)] (2**).**

4-Picoline (60 μ L, 616 mmol) was added to a solution of crude complex **1b** (150.0 mg, 0.206 mmol) in CH₂Cl₂ (30 mL) and the resulting mixture was stirred at room temperature for 2 h. The solution was concentrated to ca. 1 mL and Et₂O (20 mL) was added to precipitate a small amount of a yellow solid which was separated by filtration. The filtrate was concentrated to dryness and the residue was vigorously stirred in *n*-hexane (30 mL). The yellow solid obtained was filtered, washed with *n*-hexane (2 x 5 mL) and air-dried to afford complex **2**. Yield: 123 mg, 0.269 mmol, 65%. Mp: 156 °C dec. Anal Calcd for C₁₆H₁₉BrN₂O₂Pd (457.644): C, 41.99; H, 4.18; N, 6.12. Found: C, 41.88; H, 4.30; N, 6.21. IR (cm⁻¹): $\nu(\text{NH}) = 3316, 3248$; $\nu(\text{CO}) = 1726$. ¹H NMR (300 MHz): δ 2.36 (s, 3 H, Me), 3.25 (m, 1 H, CH₂),

3.51–3.61 (m, 2 H, CH + CH₂), 3.70 (s, 3 H, OMe), 4.24 (m, 2 H, NH₂), 6.46 (d, 1 H, H₃, C₆H₄, ³J_{HH} = 7.8 Hz), 6.73 (td, 1 H, H₄, C₆H₄, ³J_{HH} = 7.5, ⁴J_{HH} = 2.0 Hz), 6.88–6.96 (m, 2 H, H₅ + H₆, C₆H₄), 7.04 (d, 2 H, *o*-C₅H₄N, ³J_{HH} = 6.1 Hz), 8.51 (d, 2 H, *m*-C₅H₄N, ³J_{HH} = 6.4 Hz). ¹³C{¹H} NMR (75.45 MHz): δ 21.1 (s, Me), 44.8 (s, CH₂), 50.5 (s, CH), 53.0 (s, OMe), 124.5 (s, CH, C₅, C₆H₄), 125.5 (s, CH, C₄, C₆H₄), 125.7 (s, CH, *m*-C₅H₄N), 126.8 (s, CH, C₆, C₆H₄), 134.5 (s, CH, C₃, C₆H₄), 135.8 (s, C₁, C₆H₄), 147.7 (s, C₂, C₆H₄), 149.7 (s, C, *p*-C₅H₄N), 153.2 (s, CH, *o*-C₅H₄N), 171.8 (s, CO).

Single crystals of **2**, suitable for an X-ray diffraction study, were obtained by slow evaporation of a solution of **2** in CHCl₃.

Synthesis of (S)-1-oxo-3-methoxycarbonyl-1,2,3,4-tetrahydroisoquinoline (3). CO was bubbled through a suspension of **A** (from 119 mg, 0.552 mmol of phenylalanine methyl ester hydrochloride) in CHCl₃ (40 mL) for 1 hour, and the resulting mixture was stirred for 12 h in CO atmosphere. Decomposition to metallic palladium was observed. The mixture was filtered through a plug of celite and the filtrate was concentrated to dryness to give compound **3** as a colorless liquid. Yield: 72.0 mg, 0.351 mmol, 64% with respect to phenylalanine methyl ester hydrochloride. Anal. Calcd for C₁₁H₁₁NO₃ (205.213): C, 64.38; H, 5.40; N, 6.83. Found: C, 64.49; H, 5.77; N, 6.65. IR (cm⁻¹): ν(NH) = 3348, 3258; ν(CO) = 1746, 1674. ¹H NMR (400 MHz): δ 3.15, 3.26 (AB part of an “ABX system”, 2 H, CH₂, ²J_{AB} = 15.6, ³J_{BX} = 9.7, ³J_{AX} = 5.1 Hz), 3.73 (s, 3 H, OMe), 4.35 (X part of an “ABXM system”, 1 H, CH, ³J_{MX} = 2.0 Hz), 6.64 (br s, 1 H, NH), 7.17 (d, 1 H, H₅, ³J_{HH} = 7.5), 7.30 (t, 1 H, H₇, ³J_{HH} = 7.5 Hz), 7.40 (td, 1 H, H₆, ³J_{HH} = 7.5, ⁴J_{HH} = 1.4 Hz), 8.00 (dd, 1 H, H₈, ³J_{HH} = 7.5, ⁴J_{HH} = 1.2 Hz). ¹³C{¹H} NMR (100.81 MHz): δ 31.1 (s, CH₂), 52.9 (s, OMe), 53.0 (s, CH), 127.4 (s, CH, C₅), 127.5 (s, CH, C₇), 128.1 (s, CH, C₈), 128.3 (s, C_{8a}), 132.5 (s, CH, C₆), 136.1 (s, C_{4a}), 165.2 (s, CO-NH), 170.8 (s, CO₂Me). FAB⁺-MS: *m/z* 206 [(M+1)⁺].

Synthesis of (S)-1-tert-butylamino-3-methoxycarbonyl-3,4-dihydroisoquinolinium triflate (4). ^tBuNC (71 μ L, 0.628 mmol) was added to a solution of **A** (from 159 mg, 0.738 mmol of phenylalanine methyl ester hydrochloride) in acetone (20 mL), and the mixture stirred for 10 min. TlOTf (220 mg, 0.624 mmol) was added, and the resulting suspension was further stirred for 15 min. The mixture was filtered through a plug of Celite to remove TlCl. The filtrate was concentrated to dryness and the remaining residue was suspended in toluene (25 mL) and refluxed for 7 h, upon which time Pd(0) precipitated. Toluene was evaporated, acetone (20 mL) was added and the suspension was filtered through a plug of celite, and HTfO (0.1 mL, 1.13 mmol) was added. The filtrate was concentrated to dryness, the residue was dried in the oven at 70 °C for 24 h and then, dissolved in CH₂Cl₂ (3 mL). Et₂O (30 mL) was added to precipitate a white solid, which was filtered, washed with Et₂O (2 x 5 mL) and air dried to afford compound **4**. Yield: 147 mg, 0.358 mmol, 49% from phenylalanine methyl ester hydrochloride. Mp: 151 °C. Anal. Calcd for C₁₆H₂₁F₃N₂O₅S (410.411): C, 46.82; H, 5.16; N, 6.83; S, 7.81. Found: C, 46.85; H, 5.45; N, 6.93; S, 7.67. IR (cm⁻¹): ν (NH) = 3304; ν (CN) = 1752, 1640. ¹H NMR (400 MHz): δ 1.63 (s, 9 H, CMe₃), 3.30, 3.39 (AB part of an “ABX system”, 2 H, CH₂, ²J_{AB} = 16.4, ³J_{BX} = 6.2, ³J_{AX} = 4.4 Hz), 3.68 (s, 3 H, OMe), 4.86 (X part of an “ABXM system”, 1 H, CH, ³J_{MX} = 4.6 Hz), 7.31 (d, 1 H, H5, ³J_{HH} = 7.6 Hz), 7.48 (t, 1 H, H7, ³J_{HH} = 7.6 Hz), 7.59 (td, 1 H, H6, ³J_{HH} = 7.5, ⁴J_{HH} = 0.9 Hz), 8.01 (d, 1 H, H8, ³J_{HH} = 7.7 Hz), 8.07 (br s, 1 H, NH-^tBu), 8.33 (d, 1 H, NHCH, ³J_{MX} = 4.6 Hz). ¹³C{¹H} NMR (100.81 MHz): δ 28.3 (s, CMe₃), 30.1 (s, CH₂), 51.8 (s, CH), 53.3 (s, OMe), 55.3 (s, CMe₃), 121.9 (s, C8a), 127.4 (s, CH, C8), 128.8 (s, CH, C7), 128.9 (s, CH, C5), 134.9 (s, CH, C6), 135.0 (s, C4a), 156.5 (s, C1).

Single crystals of **4**, suitable for an X-ray diffraction study, were obtained by slow diffusion of *n*-hexane into a solution of **4** in CHCl₃.

Synthesis of (S)-1-(2,6-dimethylphenylamino)-3-methoxycarbonyl-3,4-dihydroisoquinolinium triflate (5). XyNC (80 mg, 0.609 mmol) was added to a solution of **A** (from 143 mg, 0.664 mmol phenylalanine methyl ester hydrochloride) in acetone (20 mL), and the mixture stirred for 10 min. TlOTf (200 mg, 0.565 mmol) was added, and the resulting suspension was further stirred for 15 min. The mixture was filtered through a plug of celite to remove TlCl. The filtrate was concentrated to dryness and the remaining residue was suspended in toluene (20 mL) and refluxed for 7 h, upon which time Pd(0) precipitated. The mixture was cooled to room temperature, toluene was evaporated, CH₂Cl₂ (45 mL) was added and the resulting suspension filtered through a plug of MgSO₄. The filtrate was concentrated to ca. 1 mL, and Et₂O (30 mL) was added to precipitate an off-white solid, which was filtered, washed with Et₂O (2 x 5 mL) and air-dried to give compound **5**. Yield: 137 mg, 0.299 mmol, 45% from phenylalanine methyl ester hydrochloride. Mp: 190-192 °C. Anal. Calcd for C₂₀H₂₁F₃N₂O₅S (458.455): C, 52.40; H, 4.62; N, 6.11; S, 6.99. Found: C, 52.20; H, 4.77; N, 6.26; S, 6.74. IR (cm⁻¹): ν(NH) = 3226 (b); ν(CN) = 2016, 1942; ν(CO) = 1752, 1644. ¹H NMR (400 MHz): δ 2.22 (s, 3 H, Me, Xy), 2.32 (s, 3 H, Me, Xy), 3.30, 3.44 (AB part of an “ABX system”, 2 H, CH₂, ²J_{AB} = 16.3, ³J_{BX} = 6.2, ³J_{AX} = 6.0 Hz), 3.70 (s, 3 H, OMe), 4.53 (X part of an “ABXM system”, 1 H, CH, ³J_{MX} = 3.9 Hz), 7.16 (d, 1 H, CHCMe, Xy, ³J_{HH} = 7.5 Hz), 7.19 (d, 1 H, CHCMe, Xy, ³J_{HH} = 7.2 Hz), 7.26 (t, 1 H, CH, Xy, ³J_{HH} = 7.5 Hz), 7.37 (br s, 1 H, NHCH), 7.40 (d, 1 H, H5, ³J_{HH} = 7.7 Hz), 7.59 (t, 1 H, H7, ³J_{HH} = 7.6 Hz), 7.70 (td, 1 H, H6, ³J_{HH} = 7.6, ⁴J_{HH} = 1.0 Hz), 8.50 (d, 1 H, H8, ³J_{HH} = 7.5 Hz), 10.90 (br s, 1 H, NH-^tBu). ¹³C {¹H} NMR (100.81 MHz): δ 17.4 (s, Me, Xy), 17.7 (s, Me, Xy), 30.4 (s, CH₂), 51.8 (s, CH), 53.7 (s, OMe), 120.3 (q, CF₃, ¹J_{CF} = 319.9 Hz), 120.6 (s, C8a), 128.2 (s, CH, C8), 128.9 (s, CH, C5), 129.3 (s, C-NH, Xy), 129.5 (s, CH, C7), 129.5 (s, CHCMe, Xy), 129.6 (s,

CHCMe, Xy), 130.3 (s, CH, Xy), 135.0 (s, C4a), 135.8 (s, CH, C6), 135.9 (s, CMe, Xy), 136.0 (s, CMe, Xy), 157.9 (s, C1), 169.2 (s, CO).

Single crystals of **5**, suitable for an X-ray diffraction study, were obtained by slow diffusion of *n*-hexane into a solution of **5** in CHCl₃.

Synthesis of *trans*-(*S,S*)-[PdBr₂{NH₂CH(CO₂Me)CH₂C₆H₄Br-2}₂] (6**).** Br₂ (220 mg, 1.376 mmol) was added to a solution of complex **1b** (500.0 mg, 0.686 mmol) in CH₂Cl₂ (25 mL) and the resulting mixture was stirred for 12 h. A dark brown solid was formed, which was filtered out, air-dried and identify as PdBr₂ (180 mg, 0.676 mmol, 98%). The filtrate was concentrated to dryness, the residue extracted with Et₂O (30 mL), the resulting solution filtered through a plug of celite, and the filtrate concentrated to dryness. The residue was vigorously stirred in *n*-pentane (30 mL) and the dark orange solid formed was filtered, washed with *n*-pentane (2 x 3 mL) and air-dried to give **6**. Yield: 376.0 mg, 0.481 mmol, 70%. Mp: 54 °C dec. Anal. Calcd for C₂₀H₂₄Br₄N₂O₄Pd (782.438): C, 30.70; H, 3.09; N, 3.58. Found: C, 30.74; H, 3.13; N, 3.45. IR (cm⁻¹): ν(NH) = 3268, 3205; ν(CO) = 1737. ¹H NMR (300 MHz): δ 2.67 (dd, 1 H, CH₂, ²J_{HH} = 13.8, ³J_{HH} = 8.4 Hz), 3.36 (m, 1 H, NH₂), 3.58 (m, 1 H, NH₂), 3.64 (dd, 1 H, CH₂, partially obscured by the OMe, ²J_{HH} = 13.8, ³J_{HH} = 6.9 Hz), 3.65 (s, 3 H, OMe), 4.27 (m, 1 H, CH), 7.13 (td, 1 H, H4, C₆H₄, ³J_{HH} = 7.8, ⁴J_{HH} = 1.8 Hz), 7.24–7.34 (m, 2 H, H5 + H6, C₆H₄), 7.56 (dd, 1 H, H3, C₆H₄, ³J_{HH} = 7.8, ⁴J_{HH} = 1.2 Hz). ¹³C{¹H} NMR (75.45 MHz): δ 40.5 (s, CH₂), 52.7 (s, OMe), 57.9 (s, CH), 125.0 (s, C2, C–Br, C₆H₄), 127.7 (s, CH, C5, C₆H₄), 129.2 (s, CH, C4, C₆H₄), 131.6 (s, CH, C6, C₆H₄), 133.2 (s, CH, C3, C₆H₄), 134.9 (s, C1, C–CH₂, C₆H₄), 171.2 (s, CO).

Synthesis of *trans*-(*S,S*)-[PdBr₂{NH₂CH(CO₂Me)CH₂C₆H₄I-2}₂] (7**).** I₂ (500 mg, 1.97 mmol) was added to a solution of complex **1b** (678 mg, 0.93 mmol) in CH₂Cl₂ (25 mL)

and the resulting mixture was stirred for 4 h. A dark brown solid was formed which was filtered out, air-dried and identify as PdI₂ (305 mg, 0.847 mmol, 91%). The suspension was filtered through a plug of Celite, the filtrate was concentrated to ca. 2 mL and *n*-pentane (30 mL) was added to precipitate a dark yellow solid which was filtered, washed with *n*-pentane (2 x 3 mL) and air-dried to give compound **7**. Yield: 715 mg, 0.816 mmol, 88%. Mp: 57 °C dec. Anal. Calcd for C₂₀H₂₄Br₂I₂N₂O₄Pd (876.44): C, 27.41; H, 2.76; N, 3.20. Found: C, 28.38; H, 2.81; N, 3.26. Compound **7** decomposes slowly at room temperature. This could explain the slightly high C analysis found (relative error, 3.5%). IR (cm⁻¹): ν(NH) = 3273, 3218; ν(CO) = 1738. ¹H NMR (300 MHz): δ 3.16 (dd, 1 H, CH₂, ²J_{HH} = 13.8, ³J_{HH} = 8.4 Hz), 3.33 (m, 1 H, NH₂), 3.53 (m, 1 H, NH₂), 3.63 (dd, 1 H, CH₂, ²J_{HH} = 13.8, ³J_{HH} = 6.9 Hz), 3.65 (s, 3 H, OMe), 4.26 (m, 1 H, CH), 6.95 (ddd, 1 H, H4, C₆H₄, ³J_{HH} = 9.0, ³J_{HH} = 6.0, ⁴J_{HH} = 3.0 Hz), 7.27–7.31 (m, 2 H, H6 + H5, C₆H₄), 7.84 (d, 1 H, H3, C₆H₄, ³J_{HH} = 8.4). ¹³C{¹H} NMR (75.45 MHz): δ 44.9 (s, CH₂), 52.8 (s, OMe), 58.1 (s, CH), 101.1 (s, C2, C-I, C₆H₄), 128.6 (s, CH, C5, C₆H₄), 129.2 (s, CH, C4, C₆H₄), 130.7 (s, CH, C6, C₆H₄), 138.2 (s, C1, C-CH₂, C₆H₄), 140.0 (s, CH, C3, C₆H₄), 171.2 (s, CO).

Synthesis of (S)-2-BrC₆H₄CH₂CH(CO₂Me)NH₂ (8**).** 1,10-Phenanthroline monohydrate (89.0 mg, 0.450 mmol) was added to a solution of complex **6** (350 mg, 0.447 mmol) in CH₂Cl₂ (25 mL) and the resulting mixture was stirred for 3 h. A yellow solid precipitated which was filtered, washed with Et₂O, air-dried and identified as [PdBr₂(phen)] by IR spectroscopy (172 mg, 0.385 mmol, 86%). The filtrate was concentrated to dryness, Et₂O (10 mL) was added and the resulting suspension filtered through a plug of celite. The filtrate was concentrated to dryness to give crude **8** as a yellow liquid. This liquid was dissolved in CH₂Cl₂ (1 mL) and subjected to silica gel preparative thin-layer chromatography. Elution with Et₂O gave a colorless band (R_f = 0.4) which was collected and extracted with

acetone; the solution was filtered through a plug of celite and the filtrate was concentrated to dryness to give pure compound **8** as a yellow liquid. Yield: 92.8 mg, 0.359 mmol, 40%. Anal. Calcd for C₁₀H₁₂BrNO₂ (258.12): C, 46.53; H, 4.67; N, 5.43. Found: C, 46.47; H, 4.83; N, 5.28. ¹H NMR (300 MHz): δ 1.64 (br s, 2 H, NH₂), 2.92 (dd, 1 H, CH₂, ²J_{HH} = 13.5, ³J_{HH} = 8.7 Hz), 3.26 (dd, 1 H, CH₂, ²J_{HH} = 13.5, ³J_{HH} = 5.7 Hz), 3.70 (s, 3 H, OMe), 3.85 (dd, 1 H, CH, ³J_{HH} = 8.7, ³J_{HH} = 5.4 Hz), 7.11 (ddd, 1 H, H4, C₆H₄, ³J_{HH} = 8.1, ³J_{HH} = 6.6, ⁴J_{HH} = 3.0 Hz), 7.20–7.26 (m, 2 H, H5 + H6, C₆H₄), 7.55 (d, 1 H, H3, C₆H₄, ³J_{HH} = 7.5 Hz). ¹³C{¹H} NMR (100.81 MHz): δ 41.3 (s, CH₂), 51.9 (s, OMe), 54.2 (s, CH), 124.7 (s, C2, C–Br, C₆H₄), 127.3 (s, CH, C5, C₆H₄), 128.4 (s, CH, C4, C₆H₄), 131.5 (s, CH, C6, C₆H₄), 132.9 (s, CH, C3, C₆H₄), 136.9 (s, C1, C–CH₂, C₆H₄), 175.2 (s, CO). FAB⁺-MS: *m/z* 258 [M(⁷⁹Br)+1]⁺, 260 [M(⁸¹Br)+1]⁺.

Synthesis of (S)-2-IC₆H₄CH₂CH(CO₂Me)NH₂ (9). 1,10-Phenanthroline monohydrate (148.8 mg, 0.751 mmol) was added to a solution of complex **7** (650 mg, 0.742 mmol) in CH₂Cl₂ (30 mL) and the resulting mixture was stirred for 3 h. A yellow solid precipitated which was filtered, washed with Et₂O, air-dried and identified as [PdBr₂(phen)] by IR spectroscopy (322.0 mg, 0.721 mmol, 97%). The filtrate was concentrated to dryness, Et₂O (10 mL) was added and the resulting suspension filtered through a plug of celite. The filtrate was concentrated to dryness to give crude **9** as a dark-yellow liquid. This liquid was dissolved in CH₂Cl₂ (1 mL) and subjected to silica gel preparative thin-layer chromatography. Elution with Et₂O gave a wide colorless band (R_f = 0.4–0.6) which was collected and extracted with acetone; the solution was filtered through a plug of celite and the filtrate was concentrated to dryness to give spectroscopically pure compound **9** as a yellow liquid. Yield: 285.3 mg, 0.935 mmol, 63%. Anal. Calcd for C₁₀H₁₂INO₂ (305.111): C, 39.37; H, 3.96; N, 4.59. Found: C, 40.01; H, 4.18; N, 4.63. Compound **9** decomposes slowly at room

temperature. This could explain the slightly high C analysis found (relative error, 1.6%). ^1H NMR (400 MHz): δ 1.79 (br s, 2 H, NH_2), 2.92 (dd, 1 H, CH_2 , $^2J_{\text{HH}} = 13.7$, $^3J_{\text{HH}} = 8.8$ Hz), 3.24 (dd, 1 H, CH_2 , $^2J_{\text{HH}} = 13.7$, $^3J_{\text{HH}} = 5.6$ Hz), 3.71 (s, 3 H, OMe), 3.85 (dd, 1 H, CH, $^3J_{\text{HH}} = 8.8$, $^3J_{\text{HH}} = 5.6$ Hz), 6.94 (td, 1 H, H4, C_6H_4 , $^3J_{\text{HH}} = 7.7$, $^4J_{\text{HH}} = 1.8$ Hz), 7.22 (dd, 1 H, H6, C_6H_4 , $^3J_{\text{HH}} = 7.6$, $^4J_{\text{HH}} = 1.7$ Hz), 7.29 (td, 1 H, H5, C_6H_4 , $^3J_{\text{HH}} = 7.5$, $^4J_{\text{HH}} = 1.2$ Hz), 7.84 (dd, 1 H, H3, C_6H_4 , $^3J_{\text{HH}} = 7.9$, $^4J_{\text{HH}} = 1.2$ Hz). $^{13}\text{C}\{^1\text{H}\}$ NMR (100.81 MHz): δ 45.6 (s, CH_2), 52.0 (s, OMe), 54.5 (s, CH), 100.8 (s, C2, C-I, C_6H_4), 128.2 (s, CH, C5, C_6H_4), 128.6 (s, CH, C4, C_6H_4), 130.7 (s, CH, C6, C_6H_4), 139.7 (s, CH, C3, C_6H_4), 140.2 (s, C1, C- CH_2 , C_6H_4), 175.0 (s, CO). FAB⁺-MS: m/z 306 [(M+1)⁺].

X-ray Structure Determinations. X-ray data for complexes **2**, **4** and **5** are summarized in Table 1. Data Collection. Crystals were mounted in inert oil on a glass fiber and transferred to a Bruker SMART APEX diffractometer. Data were recorded at low temperature and using ω scans. Multiscan absorption corrections were applied. Structure Solution and Refinements. Structures were solved by the heavy-atom method (**2**) or by direct method (**4**, **5**) and refined anisotropically on F2 using the program SHELX-97 (G. M. Sheldrick. University of Göttingen, Göttingen, Germany). Hydrogen atoms were refined as follows: NH_2 and NH, free; methyl, rigid group; all others, riding.

Acknowledgment. We thank Ministerio de Educación y Ciencia (Spain) and FEDER (CTQ2004-05396) for financial support. J.-A. G.-L. and B. C.-C. are grateful to the Ministerio de Educación y Ciencia (Spain) for their research grants.

Supporting Information Available. Details (including symmetry operators) of hydrogen bondings and listing of all refined and calculated atomic coordinates, anisotropic

thermal parameters, bond lengths and angles and CIF files for complexes **2**, **4** and **5**. This material is available free of charge via the Internet at <http://pubs.acs.org>.

References

- (1) Navarro, R.; García, J.; Urriolabeitia, E. P.; Cativiela, C.; Diaz-de-Villegas, M. *D. J. Organomet. Chem.* **1995**, 35.
- (2) Pettit, L. D.; Bezer, M. *Coord. Chem. Rev.* **1985**, 61, 97. Sabat, M.; Jezowska, M.; Kozlowski, H. *Inorg. Chim. Acta* **1979**, 37, L511. Menabue, L.; Saladini, M.; Sola, M. *Inorg. Chem.* **1990**, 29, 1293. Appleton, T. G. *Coord. Chem. Rev.* **1997**, 166, 313.
- (3) Kayser, B.; Beck, W. *Z. Naturforsch.* **2004**, 59b, 1423.
- (4) Ryabov, A. D.; Polyakov, V. A.; Yatsimirsky, A. K. *Inorg. Chim. Acta* **1984**, 91, 59.
- (5) Freiesleben, D.; Polborn, K.; Robl, C.; Sünkel, K.; Beck, W. *Can. J. Chem.* **1995**, 73, 1164.
- (6) Cope, A. C.; Friedrich, E. C. *J. Am. Chem. Soc.* **1968**, 90, 909. Bosque, R.; Maseras, F. *Eur. J. Inorg. Chem.* **2005**, 4040.
- (7) Albert, J.; Cadena, J. M.; González, A.; Granell, J.; Solans, X.; Font-Bardia, M. *F. J. Organomet. Chem.* **2002**, 666, 277. Böhm, A.; Schreiner, B.; Steiner, N.; Urban, R.; Sünkel, K.; Polborn, K.; Beck, W. *Z. Naturforsch.* **1998**, 53b, 191.
- (8) Böhm, A.; Polborn, K.; Sünkel, K.; Beck, W. *Z. Naturforsch.* **1998**, 53b, 448.
- (9) Vicente, J.; Saura-Llamas, I.; Jones, P. G. *J. Chem. Soc. Dalton Trans.* **1993**, 3619.
- (10) Vicente, J.; Saura-Llamas, I.; Palin, M. G.; Jones, P. G. *J. Chem. Soc. Dalton Trans.* **1995**, 2535. Fuchita, Y.; Tsuchiya, H.; Miyafuji, A. *Inorg. Chim. Acta* **1995**, 233, 91. Kurzeev, S. A.; Kazankov, G. M.; Ryabov, A. D. *Inorg. Chim. Acta* **2002**, 340, 192.
- (11) Vicente, J.; Saura-Llamas, I.; Palin, M. G.; Jones, P. G.; Ramírez de Arellano, M. C. *Organometallics* **1997**, 16, 826.
- (12) Albert, J.; Cadena, J. M.; Granell, J. *Tetrahedron: Asymmetry* **1997**, 8, 991.

- (13) Vicente, J.; Saura-Llamas, I.; Cuadrado, J.; Ramírez de Arellano, M. C. *Organometallics* **2003**, *22*, 5513.
- (14) Vicente, J.; Saura-Llamas, I.; Bautista, D. *Organometallics* **2005**, *24*, 6001.
- (15) Mylonas, S.; Valavanidis, A.; Voukouvalidis, V. *Inorg. Chim. Acta* **1981**, *55*, 125. Paul, A. K.; Mansuri-Torshizi, H.; Srivastava, T. S.; Chavan, S. J.; Chitnis, M. P. *J. Inorg. Biochem.* **1993**, *50*, 9. Bláha, T.; Lukes, I.; Rohovec, J.; Hermann, P. *J. Chem. Soc. Dalton Trans.* **1997**, 2621.
- (16) Mital, R.; Srivastava, T. S.; Parekh, H. K.; Chitnis, M. P. *J. Inorg. Biochem.* **1991**, *41*, 93.
- (17) Zamora, F.; González, V. M.; Pérez, J. M.; Masaguer, J. R.; Navarro-Ranninger, C. *App. Organomet. Chem.* **1997**, *11*, 659.
- (18) Higgins, J. D.; Neely, L.; Fricker, S. *J. Inorg. Biochem.* **1993**, *49*, 149. Navarro-Ranninger, C.; Lopez-Solera, I.; Perez, J. M.; Rodriguez, J.; Garcia-Ruano, J. L.; Raithby, P. R.; Masaguer, J. R.; Alonso, C. *J. Med. Chem.* **1993**, *36*, 3795. Navarro-Ranninger, C.; López-Solera, I.; González, V. M.; Pérez, J. M.; Alvarez-Valdés, A.; Martín, A.; Raithby, P.; Masaguer, J. R.; Alonso, C. *Inorg. Chem.* **1996**, *35*, 5181. Riera, X.; C *Polyhedron* **1999**, *18*, 2549. Tusek-Bozic, L.; Komac, M.; Curic, M.; Lycka, A.; D'Alpaos, M.; Scarcia, V.; Furlani, A. *Polyhedron* **2000**, *19*, 937. Rodrigues, E. G.; Silva, L. S.; Fausto, D. M.; Hayashi, M. S.; Dreher, S.; Santos, E. L.; Pesquero, J. B.; Travassos, L. R.; Caires, A. C. F. *Int. J. Cancer* **2003**, *107*, 498. Quiroga, A. G.; Navarro-Ranninger, C. *Coord. Chem. Rev.* **2004**, *248*, 119. Bincoletto, C. *Bioorg. Med. Chem.* **2005**, *13*, 3047.
- (19) Ryabov, A. D. *Synthesis* **1985**, 233. Omae, I. *Coord. Chem. Rev.* **2004**, *248*, 995.
- (20) Pfeffer, M. *Pure Appl. Chem.* **1992**, *64*, 335.
- (21) Dupont, J.; Consorti, C. S.; Spencer, J. *Chem. Rev.* **2005**, *105*, 2527.

- (22) Espuña, G.; Arsequell, G.; Valencia, G.; Barluenga, J.; Alvarez-Gutiérrez, J.; Ballesteros, A.; González, J. M. *Angew. Chem. Int. Ed.* **2004**, *43*, 325.
- (23) Barluenga, J.; García-Martín, M. A.; González, J. M.; Clapés, P.; Valencia, G. *Chem. Commun.* **1996**, 1505.
- (24) Wild, S. B. *Coord. Chem. Rev.* **1997**, *166*, 291. Camus, J.-M.; Roy-García, P.; Andrieu, J.; Richard, P.; Poli, R. *J. Organomet. Chem.* **2005**, *690*, 1659. Albert, J.; Granell, J.; Muller, G. *J. Organomet. Chem.* **2006**, *691*, 2101.
- (25) Böhm, A.; Hauck, T.; Beck, W. *Z. Naturforsch.* **1999**, *54b*, 1360. Böhm, A.; Seebach, D. *Helv. Chim. Acta* **2000**, *83*, 3262.
- (26) Kurita, J.; Usuda, F.; Yasuike, S.; Tsuchiya, T.; Tsuda, Y.; Kiuchi, F.; Hosoi, S. *Chem. Commun.* **2000**, 191. Okajima, S.; Yasuike, S.; Kakusawa, N.; Osada, A.; Yamaguchi, K.; Seki, H.; Kurita, J. *J. Organomet. Chem.* **2002**, *656*, 234.
- (27) Fuchita, Y.; Yoshinaga, K.; Ikeda, Y.; Kinoshita-Kawashima, J. *J. Chem. Soc. Dalton Trans.* **1997**, 2495.
- (28) Thompson, J. M.; Heck, R. F. *J. Org. Chem.* **1975**, *40*, 2667.
- (29) Dupont, J.; Pfeffer, M.; Daran, J. C.; Jeannin, Y. *Organometallics* **1987**, *6*, 899.
- (30) Tollari, S.; Demartin, F.; Cenini, S.; Palmisano, G.; Raimondi, P. *J. Organomet. Chem.* **1997**, *527*, 93.
- (31) O'Sullivan, R. D.; Parkins, A. W. *J. Chem. Soc. Chem. Commun.* **1984**, 1165.
- (32) Barr, N.; Bartley, J. P.; Clark, P. W.; Dunstan, P.; Dyke, S. F. *J. Organomet. Chem.* **1986**, *302*, 117.
- (33) Michel, A. G.; Walnier, A.; Durant, F. *Acta Cryst.* **1976**, *B32*, 323.
- (34) Hein, G. E.; Niemann, C. *J. Am. Chem. Soc.* **1962**, *84*, 4487.

- (35) Cohen, S. G.; Milovanovi, A.; Schultz, R. M.; Weinstein, S. Y. *J. Biol. Chem.* **1969**, *244*, 2664. Abdullaev, N. D.; Bystrov, V. F.; Rumsh, L. D.; Antonov, V. K. *Tetrahedron Lett.* **1969**, *10*, 5143.
- (36) Sellstedt, J. H.; Guinosso, C. J.; Bell, S. C., American Home Products Corp., U.S. Patent US 3928612 A.
- (37) Tang, L.; Yang, Y.-S.; Ji, R.-Y. *Chin. J. Chem.* **2002**, *20*, 1070.
- (38) Vicente, J.; Saura-Llamas, I.; Grünwald, C.; Alcaraz, C.; Jones, P. G.; Bautista, D. *Organometallics* **2002**, *21*, 3587.
- (39) Ryabov, A. D.; Kuz'mina, L. G.; Polyakov, V. A.; Kazankov, G. M.; Ryabova, E. S.; Pfeffer, M.; van Eldik, R. *J. Chem. Soc. Dalton Trans.* **1995**, 999. Calmuschi, B.; Englert, E. *CrystEngComm* **2005**, *7*, 171.
- (40) Calmuschi-Cula, B.; Kalf, I.; Wang, R.; Englert, E. *Organometallics* **2005**, *24*, 5491.
- (41) Deeming, J. A.; Rothwell, I. A.; Hursthouse, M. B.; New, L. *J. Chem. Soc. Dalton Trans.* **1978**, 1490.
- (42) Martinez-Viviente, E.; Pregosin, P. S.; Tschoerner, M. *Magn. Reson. Chem.* **2000**, *38*, 23.
- (43) Janin, Y. L.; Roulland, E.; Beurdeley-Thomas, A.; Decaudin, D.; Monneret, C.; Poupon, M.-F. *J. Chem. Soc. Perkin Trans. 1* **2002**, 529. Tsuda, Y.; Isobe, K.; Toda, J.; Taga, J. *Heterocycles* **1976**, *5*, 157. Krogsgaard-Larsen, P.; Nielsen, E. O.; Curtis, D. R. *J. Med. Chem.* **1984**, *27*, 585.
- (44) Orito, K.; Horibata, A.; Nakamura, T.; Ushito, H.; Nagasaki, H.; Yuguchi, M.; Yamashita, S.; Tokuda, M. *J. Am. Chem. Soc.* **2004**, *126*, 14342. Orito, K.; Miyazawa, M.; Nakamura, T.; Horibata, A.; Ushito, H.; Nagasaki, H.; Yuguchi, M.; Yamashita, S.; Yamazaki, H.; Tokuda, M. *J. Org. Chem.* **2006**, *71*, 5951.

- (45) Fuchita, Y.; Yoshinaga, K.; Hanaki, T.; Kawano, H.; Kinoshita-Nagaoka, J. *J. Organomet. Chem.* **1999**, *580*, 273.
- (46) Yamamoto, Y.; Yamazaki, H. *Synthesis* **1976**, 750. Yamamoto, Y.; Yamazaki, H. *Inorg. Chim. Acta* **1980**, *41*, 229. Dupont, J.; Pfeffer, M. *J. Chem. Soc. Dalton Trans.* **1990**, 3193.
- (47) Usón, R.; Forniés, J.; Espinet, P.; Lalinde, E.; Jones, P. G.; Sheldrick, G. M. *J. Chem. Soc., Dalton Trans.* **1982**, 2389. Usón, R.; Forniés, J.; Espinet, P.; Lalinde, E.; Jones, P. G.; Sheldrick, G. M. *J. Organomet. Chem.* **1983**, *253*, C47. Usón, R.; Forniés, J.; Espinet, P.; Garcia, A.; Tomas, M.; Foces-Foces, C.; Cano, F. H. *J. Organomet. Chem.* **1985**, *282*, C35. Zografidis, A.; Polborn, K.; Beck, W.; Markies, B. A.; van Koten, G. *Z Naturforsch Sect B* **1994**, *49*, 1494.
- (48) Saluste, C. G.; Crumpler, S.; Furber, M.; Whitby, R. J. *Tetrahedron Lett.* **2004**, *45*, 6995.
- (49) Onishi, M.; Hiraki, K.; Iwamoto, A. *J. Organomet. Chem.* **1984**, *262*, C11. Dunina, V. V.; Gorunova, O. N.; Grishin, Y. K.; Kuz'mina, L. G.; Churakov, A. V.; Kuchin, A. V.; Howard, J. A. K. *Russ. Chem. Bull. Int. Ed.* **2005**, *54*, 2073.
- (50) Bartolome, C.; Espinet, P.; Martín-Álvarez, J. M.; Villafañe, F. *Inorg. Chim. Acta* **2003**, *347*, 49.
- (51) Prestsch, E.; Clerc, T.; Seibl, J.; Simon, W. *Tablas para la determinación estructural por métodos espectroscópicos*; Springer-Verlag Ibérica: Barcelona, 1998.

Table 1. Crystal data and structure refinement for compounds **2**, **4** and **5**.

| | 2 | 4 | 5 |
|---|--|--|--|
| formula | C ₁₆ H ₁₉ BrN ₂ O ₂ Pd | C ₁₆ H ₂₁ F ₃ N ₂ O ₅ S | C ₂₀ H ₂₁ F ₃ N ₂ O ₅ S |
| fw | 457.64 | 410.41 | 458.45 |
| crystal syst | monoclinic | monoclinic | monoclinic |
| space group | P 2(1) | P 2(1) | P 2(1) |
| temperature | 100(2) K | 100(2) K | 100(2) K |
| <i>a</i> (Å) | 8.2295(7) | 9.5247(4) | 9.3942(7) |
| <i>b</i> (Å) | 9.2912(8) | 10.0175(4) | 11.5392(9) |
| <i>c</i> (Å) | 11.3389(12) | 9.8917(4) | 10.2024(8) |
| α (deg) | 90 | 90 | 90 |
| β (deg) | 91.663(2) | 93.333(2) | 99.789(2) |
| γ (deg) | 90 | 90 | 90 |
| volume (Å ³) | 866.63(14) | 942.21(7) | 1089.85(15) |
| <i>Z</i> | 2 | 2 | 2 |
| ρ_{calcd} (Mg m ⁻³) | 1.754 | 1.447 | 1.397 |
| μ (Mo, K α) (mm ⁻¹) | 3.383 | 0.230 | 0.208 |
| <i>F</i> (000) | 452 | 428 | 476 |
| cryst size (mm) | 0.24 x 0.05 x 0.05 | 0.50 x 0.35 x 0.17 | 0.24 x 0.19 x 0.09 |
| θ range (deg) | 2.48 to 27.48 | 2.06 to 26.37 | 2.20 to 26.37 |
| no. of reflns coll | 10153 | 10381 | 12039 |
| no. of indep reflns | 3930 | 3831 | 4419 |
| <i>R</i> _{int} | 0.0382 | 0.0145 | 0.0281 |
| max. and min. transmsn | 0.8491 and 0.4973 | 0.9619 and 0.8935 | 0.9816 and 0.9519 |

| | | | |
|--|------------------|------------------|------------------|
| no. of data/restraints/params | 3930/10/210 | 3831/1/257 | 4419/1/291 |
| goodness-of-fit on F^2 | 1.024 | 1.079 | 1.033 |
| R1 [$I > 2\sigma(I)$] | 0.0353 | 0.0265 | 0.0399 |
| wR2 (all reflns) | 0.0796 | 0.0677 | 0.0972 |
| Flack parameter | 0.0035(10) | 0.03(5) | -0.08(7) |
| largest diff. peak and hole ($e \text{ \AA}^{-3}$) | 1.432 and -0.951 | 0.211 and -0.260 | 0.393 and -0.176 |

For the Table of contents

Some orthopalladated L-phenylalanine methyl ester complexes have been prepared and used to synthesize several heterocyclic compounds and orthohalo derivatives.

